Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News information

Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award

Page View:
On April 20th, the "2021 Drug Innovation Award", sponsored by Securities Times, was officially released after rounds of the company's self-recommendation, recommendation, online voting and expert selection.
Shanghai Medicilon Inc. (Medicilon) was listed on the "Top Ten Drug Innovation Service Organizations of the Year".

drug innovation.jpg

The "2021 Drug Innovation Award" aims to promote the development of the innovative drug industry through the selection of outstanding drug innovation individuals, projects and enterprises in China. The event attracted the participation of nearly 100 pharmaceutical and innovative drug R&D companies and drew extensive attention from industry experts and academia.
Innovation is the development strategy that Medicilon has always adhered to.  In the process of development, Medicilon has always strengthened R&D innovation with a global perspective such as vigorously developing drug R&D technologies with independent IP rights, forward-looking layout of a diversified and high-tech innovative R&D service platform, facilitating the cross-integration of new drug R&D, big data and AI, and hire and train the high-end innovative talent teams.  Medicilon continues to focus the importance on multi-dimensional innovation and enhances its core competitiveness for sustainable high-quality development.
Innovation drives the continuous upgrading and expansion of services, and also drives the continuous development and growth of Medicilon.  Medicilon has carried out diversified collaboration with 1,460 pharmaceutical companies, research institutions and scientific researchers around the world, providing one-stop R&D services from lead compound screening and optimization to new drug clinical approval application.  Medicilon has successfully assisted the registration of 221 IND R&D projects, and actively boost the speed and efficiency, and lower the cost of new drug R&D.
Relevant newsRelevant news